ErbBs in lung cancer

Experimental Cell Research
Sreenath V Sharma, Jeffrey Settleman

Abstract

Lung cancer remains the leading cause of cancer deaths worldwide, and advanced stage disease is largely refractory to conventional chemotherapy. Thus, there is an important need for alternative treatment strategies, and the ErbB proteins have emerged as potentially important therapeutic drug targets in this setting, apparently reflecting a state of "oncogene addiction" in some lung tumors. In this review, we discuss the recent identification of mutations that promote activation of ErbB family proteins in a subset of lung cancers, and the development of selective inhibitors of these proteins that have demonstrated clinical efficacy. We also discuss the problem of drug resistance, which severely limits the clinical utility of such agents, and has prompted intense efforts to better understand molecular mechanisms underlying drug resistance as well as strategies to overcome or prevent such resistance.

References

Jan 1, 1992·Molecular Carcinogenesis·D ShiM C Hung
May 11, 1991·Journal of Clinical Immunology·H M ShepardA Ullrich
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M TateishiK Sugimachi
Jul 20, 1994·Journal of the National Cancer Institute·H AdlercreutzE Hämäläinen
Aug 16, 1994·Proceedings of the National Academy of Sciences of the United States of America·P M GuyK L Carraway
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·D W FryE M Dobrusin
Feb 6, 1999·International Journal of Cancer. Journal International Du Cancer·R A HarrisM J O'Hare
Apr 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·L N KlapperY Yarden
Oct 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R I NicholsonM E Harper
Feb 7, 2002·The European Respiratory Journal·E BrambillaY Shimosato
Jul 6, 2002·Science·I Bernard Weinstein
Aug 28, 2002·The Journal of Biological Chemistry·Jennifer StamosCharles Eigenbrot
Jul 11, 2003·Proceedings of the National Academy of Sciences of the United States of America·Thomas HolbroNancy E Hynes
Sep 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fred R HirschWilbur A Franklin
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T KurataM Fukuoka
Jan 24, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Murthy GollamudiJeffrey A Kern
Jun 17, 2004·Journal of the National Cancer Institute·Alison M DunningBruce A J Ponder
Jul 31, 2004·Science·Raffaella SordellaJeffrey Settleman
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Oct 1, 2004·Nature·Philip StephensMichael R Stratton
Oct 22, 2004·Human Molecular Genetics·Soji KakiuchiYusuke Nakamura
Dec 2, 2004·Nature Reviews. Drug Discovery·Henrik DaubAxel Ullrich
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shiu-Feng HuangShih-Feng Tsai
Feb 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sae-Won HanNoe Kyeong Kim
Feb 16, 2005·Nature Biotechnology·Miles A FabianDavid J Lockhart
Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Feb 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey A EngelmanLewis C Cantley

❮ Previous
Next ❯

Citations

Jul 24, 2014·CNS Oncology·Anna MinchomMary O'Brien
Mar 23, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jing WenMing Guo
Aug 26, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·M Teresa Agulló-OrtuñoLuis Paz-Ares
Sep 8, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Ijeoma Adaku UmeloJacques De Grève
Aug 27, 2013·The Annals of Thoracic Surgery·Julissa JuradoWilliam Bulman
Jan 28, 2014·Translational Oncology·Gianluca SalaUNKNOWN Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)
Feb 2, 2010·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Miriam ColomboPaolo Verderio
Feb 12, 2009·Current Opinion in Cell Biology·Nancy E Hynes, Gwen MacDonald
Mar 15, 2011·Cancer Cytopathology·Shahreen BillahMing Guo
Mar 1, 2015·European Journal of Pharmacology·Seyyed Mortaza HaghgooIan M Adcock
May 15, 2015·Proceedings of the National Academy of Sciences of the United States of America·Hsin-Yung YenChi-Huey Wong
Mar 13, 2014·Cancer Biology & Therapy·Paul Dent
Oct 16, 2010·Cell·Anke BillMichael Famulok
Oct 23, 2016·Clinical Lung Cancer·David M DiBardinoWilliam A Bulman
Oct 3, 2013·International Journal of Oncology·Hyunjeong SeoBuhyun Youn
Dec 18, 2010·Oncotarget·Zhenfeng ZhangBalazs Halmos
Jun 7, 2013·International Journal of Molecular Medicine·Hee-Kyoung ParkTaek-Jeong Nam
Dec 30, 2017·International Journal of Molecular Medicine·Lian-Wei LiGe Lou
Sep 23, 2018·Nature Communications·Martin BaumdickPhilippe I H Bastiaens
Jan 20, 2021·Nature Reviews. Cancer·Shogo KumagaiHiroyoshi Nishikawa
Apr 5, 2012·Genes & Development·Jeremy S Logue, Deborah K Morrison

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.